In silico analysis of kaempferol as a competitor of estrogen on estrogen receptor alpha of endometrial cancer by Suryani, Yani et al.
Journal of Physics: Conference Series
PAPER • OPEN ACCESS
In silico analysis of kaempferol as a competitor of estrogen on estrogen
receptor alpha of endometrial cancer
To cite this article: S Yani et al 2019 J. Phys.: Conf. Ser. 1402 066109
 
View the article online for updates and enhancements.
This content was downloaded from IP address 36.72.41.184 on 26/05/2020 at 05:47
Content from this work may be used under the terms of the Creative Commons Attribution 3.0 licence. Any further distribution
of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI.
Published under licence by IOP Publishing Ltd
4th Annual Applied Science and Engineering Conference










In silico analysis of kaempferol as a competitor of estrogen on 
estrogen receptor alpha of endometrial cancer 
S Yani1,*, T Opik1,2, R Siti1, K Ida1 and P Epa1 
1 Department of Biology, Faculty of Science and Technology, UIN Sunan Gunung 
Djati, Bandung, Jl. AH. Nasution No. 105 Bandung 




Abstract. In-silico study of kaempferol has been performed to determine its potential as a natural 
estrogen competitor in an effort to suppress the growth of endometrial cancer. This study used a 
method of molecular decelerating of kaempferol against estrogen receptor alpha, which is 
compared with natural estrogen in the body. The research process was conducted at the 
Laboratory of Biology Department of Science and Technology Faculty of UIN Sunan Gunung 
Djati Bandung, from December 2017 until February 2018. The software used in this study is 
PyRx-Virtual Screening Tools (for molecular docking process) and Discovery Studio (for pose 
visualization and data analysis). The results showed that kaempferol is a potential natural 
estrogen competitor. It is indicated by the lower binding affinity value of kaempferol (-7.0 
kcal/mol) than the binding affinity of natural estrogen (-6.7 kcal/mol). The low-affinity binding 
value shows a stable interaction. This means that Kaempferol is a potential phytoestrogen for 
cancer therapy without side effects. 
1.  Introduction 
Endometrial cancer is a gynaecologic malignant tumour that often occurs in women. Endometrial cancer 
begins when cells in the inner lining of the uterus (endometrium) grow uncontrollably. According to 
Cancer Research UK, 73% of these diseases are diagnosed in women of middle age (40 to 70 years of 
age) and about 25% are diagnosed at age of 75 or older. Age-related rates are increasing in countries 
where an economic transition from low to high happens [1]. One of the factors that cause endometrial 
cancer is estrogen uses in hormone therapies. Estrogen is used without progesterone combination in 
hormone therapy for contraception [2]. Estrogen initiates the growth of endometrial cancer cells through 
estrogen receptor Alpha (REα) [3]. Another estrogen use is hormone therapy with tamoxifen. Tamoxifen 
is used in treatments of breast and endometrial cancer. Tamoxifen is an artificial estrogen that acts as an 
anti-estrogen at the binding of REα and blocks its signalling pathway in cancer cells [4]. Unfortunately, 
in practice, the use of tamoxifen has a side effect. It triggers other endometrial cancer. Therefore, a 
natural estrogen (phytoestrogen) is required for hormone therapies. 
Phytoestrogens are the right choice for hormone therapy. One of the phytoestrogen types assumed to 
have pharmacological activities of anticancer is kaempferol. Kaempferol is a type of flavonoid. Vega et 
al reported that they have isolated kaempferol and tested its activity as an inhibitor of cancer cell growth 
in Erlich carcinoma [5]. Likewise, Yoshida et al reported that the treatment of cancer cells with 
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kaempferol can suppress cancer cell populations with low effects on normal cells and can strengthen the 
toxic effects of chemotherapy to fight against cancer cells [6]. Inspired by the two previous reports, a 
study of kaempferol in suppressing endometrial cancer cells is necessary. 
In-Silico study is a simulation method in an attempt to explain the pharmacological potential of a 
compound. One of the most commonly used methods is molecular docking [7]. This method is very 
effective to explain the pharmacological potential of a compound [8]. Therefore, in-silico study with 
molecular docking method is chosen to investigate the potential of kaempferol as a estrogen competitor 
that can bind to estrogen receptor alpha. 
2.  Material and methodology 
2.1.  Tools and materials 
2.1.1.  Tools. The required tools consist of hardware and software. The hardware involved Intel Celeron 
N3050 with HD graphics, 2 GB RAM, 64-bit operating system, and 500 GB Hard disk. The used 
software are PyRx-AutoDock Vina and Discovery studio. 
2.1.2.  Material. The material comprises a three-dimensional structure of estrogen receptor alpha (REα) 
with the code of 3DT3, which is downloaded from the website of protein data bank 
http://www.rcsb.org./pdb/explore/explore.do/structureId=3DT3 and a three-dimensional structure of 
kaempferol and 17β-estradiol (natural estrogen for control experiment), downloaded from the site of 
databank zinc.docking.org. The three-dimensional structure of kaempferol is in the form of .mol2 code 
ZINC03869768 and three-dimensional structure 17β-estradiol is in the form of .mol2 code 
ZINC03815415. 
2.2.  Procedure 
2.2.1.  Protein preparation. The REα protein is separated by water and ligand molecules with Discovery 
Studio version 4.5. Then, it is stored in a .pdb format. Next, with Autodock Vina 4.2, the hydrogen atom 
of the protein is displayed and stored in a .pdbqt format. 
2.2.2.  Gridbox determination. Determination of Gridbox of kaempferol is at the receptor site (REα) 
with the centre X: 39.3698, Y: -0.7673, Z: 14.1718 and the large dimension with the angstrom X: 25.00, 
Y: 25.00, Z: 25.00. Determination of 17β-estradiol ligand grid box is at the location of protein receptors 
with the centre 42.3941, Y: 1.5089, Z: 16.8038 and the large dimensions with the angstrom X: 25.00, 
Y: 25.00, Z: 25.00. 
2.2.3.  Molecular docking. Molecular docking in this study is docking- oriented because it determines 
the grid box as a target of molecular docking. Requirements for the docking with AutoDock Vina are 
that ligands and receptors must be in a .pdbqt format. There are grid box and configuration. The 
configuration must include receptor names, ligand names, file out with a .pdbqt format, a grid centre, 
and a grid size. The structural data needs to change from a .pdb extension format to a .pdbqt format. The 
.pdb format in the ligand and receptor shows no charge on the molecule, whereas the .pdbqt format 
indicates a partial charge on each atom. 
2.2.4.  Visualization and conformation analysis. Visualization of kaempferol poses and 17β-estradiol on 
receptors (REα) uses Discovery Studio software version 4.5. 
3.  Result and discussion 
Analysis of molecular docking results was conducted on the resulted energy of binding affinity, the Root 
Mean Square Deviation (RMSD) value, the amount and type of interactions between the ligand with the 
amino acid in REα. The molecular docking process produces nine ligand-receptor conformations. The 
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best of the nine conformations is selected based on the lowest RMSD value. RMSD is the value of 
deviation between the moored ligand conformations of the x-ray ligand. 
3.1.  Visualization of conformation of docking result 
 
Figure 1. Ligan-REα conformation. 
In Figure 1 is the positions of kaempferol (blue) and 17β-estradiol (red) are on the same adhesive side 
of REα. This shows that both compounds have the same potential to fill the active side of REα. Based 
on figure kaempferol will be a strong competitor compound for estrogen. 
The following is a clear visualization of the conformation of each ligand (kaempferol and 17β-
Estradiol with Reα). 
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Figure 2 shows a formed bond between the kaempferol and the amino acid residues of REα, namely 
Leusin 354, Aspartic Acid 351, Alanine 350, Triptofan 383, Leusin 536, Leusin 525, Tyrosin 526 and 
Aspartic Acid 532. 
 
Figure 3. Visualization of 17β-estradiol and Reα pose. 
Figure 3 shows the 17β-estradiol pose in the REα bonding sac, showing the interaction of 17β-estradiol 
compounds with Leucine 536, Triptofan 383, Tyrosin 526 and Leusin 525 in Reα. 
The molecular docking result produces an affinity binding value to determine the conformation 
quality. The following table illustrates a comparison of the binding affinity values of both molecules 
resulted in the molecular docking. 
Table 1. Comparison of affinity binding values of kaempferol and 17β-estradiol. 




Table 1 shows that kaempferol has a low affinity binding value of -7.0 kcal / mol. This value is lower 
than the natural estrogen (17β-estradiol) with -6.7 kcal / mol. accordingly, the caemferol has a more 
stable bond to REα than the natural estrogen. This value is supported by the number of interactions 
formed between the ligand and Reα. The interactions are illustrated in Table 2. 
Table 2. Comparison of the interactions of Kaempferol-REα with 17β-estradiol-Reα. 
Compound Name 






Kaempferol 2 6 1 
17β-estradiol 1 4 0 
 
According to Table 2, the taempferol-REα conformation has a greater number of interaction than the 
17β-estradiol-REα conformation. This supports the potential of kaemferol to be a natural estrogen-
competitor. 
4.  Conclusion 
The kaempferol can become an estrogen competitor to replace the role of 17βestradiol ligand 
(endogenous estrogen) to bind to REα. The lower affinity-binding value means the more stable 
interaction due to the stronger binding to REα, as a result it potentially plays as an estrogen competitor 
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in Reα. Multiple molecular dynamics are required to know the stability of more detailed interactions in 
the body. In-vitro and in-vivo tests are necessary to determine the activity of kaempferol as anti-
endometrial cancer. 
References 
[1] Jackson A, Bandera E, Clinton S, Giovannucci E, Hursting S and Leitzmann M 2013 Endometrial 
Cancer 2013 Report, Food, Nutrition, Physical Activity and the Prevention of Endometrial 
Cancer World Cancer Research Fund 1-30 
[2] Farquar C M, Lethaby A, Shower M, Verry J and Baranyai J 1999 An Evaluation of Risk Factor 
for Endometrial Hyperplasia in Premenopousal Woman with Abnormal Menstrual Bleeding 
Am J Obstet Gynecol 181 3 525 
[3] Marino M, Galluzzo P and Ascenzi P 2006 Estrogen Signaling Multiple Pathways to Impact Gene 
Transcription Curr Genomics 7 497–508 
[4] Swerdlow A J, Jones M E and British 2005 Tamoxifen Second Cancer Study Group. Tamoxifen 
Treatment for Breast Cancer and Risk of Endometrial Cancer: A Case-Control Study J Natl 
Cancer Inst. 97 375-384 
[5] Yoshida T 2008 Kaempferol sensitizes colon cancer cells to TRAILinduceed apoptosis 
Biochemistry Biophysics Commun. 375 129-133 
[6] Vega M R G 2007 Flavonoids from Annona dioica leaves and their effects in Erlich carcinoma 
cells, DNA-topoisomerase I and II Journal Brazzil Chemistry Society 18 1554-1559 
[7] Lengauer T and Rarey M 1996 Computational Methods for Biomolecular Docking Curr 
OpinStruct Biol. 6 3 402-406 
 
 
